Tenax Therapeutics has completed a pharmacological assessment of TNX-201, the company’s new oral formulation of imatinib for pulmonary arterial…
Articles by Marisa Wexler, MS
Pulmonary Hypertension News brought you the latest coverage of advances in treatment, clinical trials, and scientific research related to…
Care at a specialty center is tied to a lower risk of hospitalization for people with heart failure with preserved ejection fraction…
Children with pulmonary arterial hypertension (PAH) report poorer health-related quality of life (HRQoL) than their peers, a study shows.
Aerovate Therapeutics is starting a Phase 2b/3 clinical trial that will test AV-101, the company’s experimental inhaled formulation of imatinib,…
Beyond Air has announced that it is not expecting the U.S. Food and Drug Administration (FDA) to approve its …
Treatment with the experimental medication KER-012 helped to prevent heart damage in a mouse model of pulmonary hypertension,…
By analyzing how medications affect the genetic activity of cells, researchers developed a computational pipeline that may be useful in…
Due to problems at a third-party facility, the U.S. Food and Drug Administration (FDA) has decided to not approve Tyvaso…
People with pulmonary hypertension (PH) who start treatment with opioids to manage pain after undergoing surgery are at high…
The U.S. Food and Drug Administration (FDA) has cleared Tenax Therapeutics to begin clinical testing of its new oral…
Targeting a protein called p110a, a part of the PI3K family of enzymes, may be useful for preventing or even…